Comparative Pharmacology
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEDULIN versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5.
HEDULIN vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEDULIN (phenindione) is an anticoagulant that inhibits vitamin K-dependent synthesis of coagulation factors II, VII, IX, and X in the liver, thereby reducing thrombus formation.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa), thereby preventing fibrin clot formation and extension.
Oral, 200-400 mg initially, then 100-200 mg every 6-12 hours; maximum daily dose 1200 mg.
Loading dose: 5000 units IV bolus, then continuous IV infusion at 12,000-18,000 units/24h (10-15 units/kg/h). Adjust to target aPTT 60-80 seconds.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in patients with normal renal function; may be prolonged to 30-40 hours in renal impairment, necessitating dose adjustment.
The terminal elimination half-life of heparin is dose- and concentration-dependent, averaging 1-2 hours after intravenous administration. At therapeutic doses, the half-life is approximately 1.5 hours; with higher doses, it can extend to 2.5-3 hours. The half-life is prolonged in patients with hepatic or renal impairment.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; the remainder is metabolized hepatically and excreted in feces via bile.
Heparin is eliminated primarily via the reticuloendothelial system and liver, with renal excretion of metabolites accounting for approximately 50-60% of the dose. A small fraction (up to 5%) is excreted unchanged in urine. No significant biliary or fecal elimination.
Category C
Category A/B
Anticoagulant
Anticoagulant